Sotac Pharmaceuticals (NSE:SOTAC) Ending Cash Position: ₹-10.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SOTAC Sotac Pharmaceuticals Ltd NSE:SOTAC
50 GF Score
Price ₹90.05
GF Value ₹142.88
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sotac Pharmaceuticals Ending Cash Position?

Sotac Pharmaceuticals NSE:SOTAC 50 Ending Cash Position is ₹-10.2 Mil as of Mar. 2026. GuruFocus rates NSE:SOTAC with a GF Score™ of 50/100 and a GF Value™ of ₹142.88 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Sotac Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was ₹-10.2 Mil.

Sotac Pharmaceuticals's quarterly Ending Cash Position increased from Mar. 2025 (₹10.4 Mil) to Sep. 2025 (₹22.0 Mil) but then declined from Sep. 2025 (₹22.0 Mil) to Mar. 2026 (₹-10.2 Mil).

Sotac Pharmaceuticals's annual Ending Cash Position declined from Mar. 2024 (₹34.2 Mil) to Mar. 2025 (₹15.6 Mil) and declined from Mar. 2025 (₹15.6 Mil) to Mar. 2026 (₹11.8 Mil).

Sotac Pharmaceuticals Ending Cash Position Related Terms

Sotac Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sotac Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals Ending Cash Position Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial 0.28 96.82 34.18 15.64 11.78

Sotac Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 19.58 5.21 10.43 22.00 -10.22
NSE:SOTAC
50GF Score
Sotac Pharmaceuticals Ltd NSE:SOTAC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sotac Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sotac Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=15.639+-3.859
=11.8

Sotac Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.5527136788005E-15+-10.221
=-10.2

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹-10.2 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Ending Cash Position of ₹-10.2 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sotac Pharmaceuticals and its competitors.
Is Sotac Pharmaceuticals' Ending Cash Position too high?
Sotac Pharmaceuticals' current Ending Cash Position is ₹-10.2 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Ending Cash Position compare to ZTS?
Sotac Pharmaceuticals' Ending Cash Position of ₹-10.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sotac Pharmaceuticals and its competitors. Sotac Pharmaceuticals's current Ending Cash Position is ₹-10.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹142.88, compared to a current price of ₹90.05 — trading 37% below its estimated fair value. The current Ending Cash Position is ₹-10.2 Mil. Sotac Pharmaceuticals' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Ending Cash Position is ₹-10.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued. The current stock price of ₹90.05 is trading 37% below its estimated GF Value™ of ₹142.88. GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:SOTAC:

  • Ending Cash Position: ₹-10.2 Mil
  • GF Value™: ₹142.88 vs. price of ₹90.05 (37% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotac Pharmaceuticals Business Description

Address Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
50GF Score

Get the complete analysis for NSE:SOTAC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹90.05
Price
₹142.88
GF Value